{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:51:09Z","timestamp":1790013069582,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T00:00:00Z","timestamp":1534809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41416-018-0123-9","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T11:10:19Z","timestamp":1534849819000},"page":"1052-1059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)"],"prefix":"10.1038","volume":"119","author":[{"given":"Nuria","family":"Romero-Laorden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Jayaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Saez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Montesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gutierrez-Pecharoman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Villatoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rosero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda I.","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Garc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ylenia","family":"Cend\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma Paz","family":"Nombela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floortje","family":"Van de Poll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gala","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro P.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Jes\u00fas","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3691-6454","authenticated-orcid":false,"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,21]]},"reference":[{"key":"123_CR1","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS Bono de","year":"2011","unstructured":"de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995\u20132005 (2011).","journal-title":"N. Engl. J. Med."},{"key":"123_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138\u2013148 (2013).","journal-title":"N. Engl. J. Med."},{"key":"123_CR3","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-08-4531","volume":"69","author":"G Attard","year":"2009","unstructured":"Attard, G., Reid, A. H., Olmos, D. & de Bono, J. S. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 69, 4937\u20134940 (2009).","journal-title":"Cancer Res."},{"key":"123_CR4","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","volume":"27","author":"G Attard","year":"2009","unstructured":"Attard, G. et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742\u20133748 (2009).","journal-title":"J. Clin. Oncol."},{"key":"123_CR5","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563\u20134571 (2008).","journal-title":"J. Clin. Oncol."},{"key":"123_CR6","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","volume":"28","author":"AH Reid","year":"2010","unstructured":"Reid, A. H. et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28, 1489\u20131495 (2010).","journal-title":"J. Clin. Oncol."},{"key":"123_CR7","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","volume":"28","author":"DC Danila","year":"2010","unstructured":"Danila, D. C. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28, 1496\u20131501 (2010).","journal-title":"J. Clin. Oncol."},{"key":"123_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.eururo.2014.10.004","volume":"67","author":"R Venkitaraman","year":"2015","unstructured":"Venkitaraman, R. et al. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur. Urol. 67, 673\u2013679 (2015).","journal-title":"Eur. Urol."},{"key":"123_CR9","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1038\/bjc.2014.531","volume":"111","author":"D Lorente","year":"2014","unstructured":"Lorente, D. et al. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br. J. Cancer 111, 2248\u20132253 (2014).","journal-title":"Br. J. Cancer"},{"key":"123_CR10","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148\u20131159 (2008).","journal-title":"J. Clin. Oncol."},{"key":"123_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"123_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.eururo.2014.10.027","volume":"67","author":"R Ferraldeschi","year":"2015","unstructured":"Ferraldeschi, R. et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur. Urol. 67, 795\u2013802 (2015).","journal-title":"Eur. Urol."},{"key":"123_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/sj.onc.1210640","volume":"27","author":"G Attard","year":"2008","unstructured":"Attard, G. et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27, 253\u2013263 (2008).","journal-title":"Oncogene"},{"key":"123_CR14","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","volume":"28","author":"V Conteduca","year":"2017","unstructured":"Conteduca, V. et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann. Oncol. 28, 1508\u20131516 (2017).","journal-title":"Ann. Oncol."},{"key":"123_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/sim.721","volume":"20","author":"RP A\u2019Hern","year":"2001","unstructured":"A\u2019Hern, R. P. Sample size tables for exact single-stage phase II designs. Stat. Med. 20, 859\u2013866 (2001).","journal-title":"Stat. Med."},{"key":"123_CR16","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher, H. I. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J. Clin. Oncol. 34, 1402\u20131418 (2016).","journal-title":"J. Clin. Oncol."},{"key":"123_CR17","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","volume":"17","author":"GJ Bubley","year":"1999","unstructured":"Bubley, G. J. et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J. Clin. Oncol. 17, 3461\u20133467 (1999).","journal-title":"J. Clin. Oncol."},{"key":"123_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnci\/djj129","volume":"98","author":"DP Petrylak","year":"2006","unstructured":"Petrylak, D. P. et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J. Natl. Cancer Inst. 98, 516\u2013521 (2006).","journal-title":"J. Natl. Cancer Inst."},{"key":"123_CR19","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.eururo.2016.02.055","volume":"70","author":"P Rescigno","year":"2016","unstructured":"Rescigno, P. et al. Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer. Eur. Urol. 70, 724\u2013731 (2016).","journal-title":"Eur. Urol."},{"key":"123_CR20","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","volume":"26","author":"S Gillessen","year":"2015","unstructured":"Gillessen, S. et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann. Oncol. 26, 1589\u20131604 (2015).","journal-title":"Ann. Oncol."},{"issue":"1","key":"123_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.eururo.2017.07.035","volume":"74","author":"Johann S. de Bono","year":"2018","unstructured":"de Bono J. S. et al. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for \u226524 weeks in Europe. Eur. Urol. (2017). \n                    https:\/\/doi.org\/10.1016\/j.eururo.2017.07.035\n                    \n                  .","journal-title":"European Urology"},{"key":"123_CR22","doi-asserted-by":"crossref","unstructured":"Gillessen S., et al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur. Urol. 73, 178\u2013211 (2017).","DOI":"10.1016\/j.eururo.2017.06.002"},{"key":"123_CR23","doi-asserted-by":"publisher","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","volume":"7","author":"A Romanel","year":"2015","unstructured":"Romanel, A. et al. Plasma AR and abiraterone-resistant prostate cancer. Sci. Transl. Med. 7, 312re10 (2015).","journal-title":"Sci. Transl. Med."},{"key":"123_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ijc.10495","volume":"100","author":"K Steketee","year":"2002","unstructured":"Steketee, K. et al. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J. Cancer 100, 309\u2013317 (2002).","journal-title":"Int J. Cancer"},{"key":"123_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1210\/jc.2011-2189","volume":"97","author":"G Attard","year":"2012","unstructured":"Attard, G. et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J. Clin. Endocrinol. Metab. 97, 507\u2013516 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"123_CR26","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1158\/1078-0432.CCR-14-1961","volume":"21","author":"G Attard","year":"2015","unstructured":"Attard, G. et al. Improvements in radiographic progression-free survival stratified by erg gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Clin. Cancer Res. 21, 1621\u20131627 (2015).","journal-title":"Clin. Cancer Res."},{"key":"123_CR27","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028\u20131038 (2014).","journal-title":"N. Engl. J. Med."},{"key":"123_CR28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora, V. K. et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155, 1309\u20131322 (2013).","journal-title":"Cell"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0123-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0123-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0123-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:30Z","timestamp":1684616550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0123-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,21]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["123"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0123-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,21]]},"assertion":[{"value":"25 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RL, GA, EC and DO have received research funding from Janssen. NRL, FLC, MIS, AM, BH, JJC, DL, GA, EC and DO have received speaker fees from Janssen. GA, EC and DO have received consulting fees from Janssen. AJ and GA are employees of The ICR, who developed abiraterone, and therefore have a commercial interest in this agent. GA is on the ICR list of rewards to inventors for abiraterone.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the institutional ethics review committees of all participating centres and was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation\/WHO Good Clinical Practice standards. All patients provided informed consent to enter the study at the time of enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}